1. Protein Tyrosine Kinase/RTK Neuronal Signaling GPCR/G Protein
  2. DYRK 5-HT Receptor
  3. Harmine

Harmine (GMP) (Telepathine (GMP)) is Harmine (HY-N0737A) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT2A serotonin receptor, with an Ki of 397 nM.

For research use only. We do not sell to patients.

Harmine

Harmine Chemical Structure

CAS No. : 442-51-3

Size Price Stock Quantity
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Harmine (GMP) (Telepathine (GMP)) is Harmine (HY-N0737A) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT2A serotonin receptor, with an Ki of 397 nM[1].

Cellular Effect
Cell Line Type Value Description References
1A9 ED50
1.6 μg/mL
Compound: 3
In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line
In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line
[PMID: 10612592]
769-P IC50
48.9 μM
Compound: 7
Cytotoxicity against human renal carcinoma 769-P cells assessed as reduction in optical density by MTT assay
Cytotoxicity against human renal carcinoma 769-P cells assessed as reduction in optical density by MTT assay
[PMID: 23279863]
A-375 IC50
72.5 μM
Compound: 7
Cytotoxicity against human malignant melanoma A375 cells assessed as reduction in optical density by MTT assay
Cytotoxicity against human malignant melanoma A375 cells assessed as reduction in optical density by MTT assay
[PMID: 23279863]
A549 ED50
2.4 μg/mL
Compound: 3
In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line
In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line
[PMID: 10612592]
A549 IC50
17.12 μM
Compound: Harmine
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 34425477]
A549 IC50
17.3 μM
Compound: Cpd I
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
[PMID: 38154256]
A549 IC50
42.25 μM
Compound: Harmine
Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
[PMID: 27397495]
A549 IC50
5.23 μM
Compound: HM
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
[PMID: 35341920]
A549 IC50
5.89 μM
Compound: Harmine
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay
[PMID: 31227365]
A549 IC50
52.56 μM
Compound: 6; Harmine
Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
Antiproliferative activity against human A549 cells after 24 hrs by MTT assay
10.1039/C5MD00581G
A549 IC50
7.76 μM
Compound: Har
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
[PMID: 29129513]
A549 IC50
> 20 μM
Compound: Harmine
Antiproliferative activity against human A549 cells
Antiproliferative activity against human A549 cells
[PMID: 37875056]
BGC-823 IC50
15.63 μM
Compound: HM
Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
[PMID: 35341920]
BGC-823 IC50
63.2 μM
Compound: 7
Cytotoxicity against human gastric carcinoma BGC823 cells assessed as reduction in optical density by MTT assay
Cytotoxicity against human gastric carcinoma BGC823 cells assessed as reduction in optical density by MTT assay
[PMID: 23279863]
BGC-823 IC50
68 μM
Compound: 1
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
[PMID: 23291116]
BGC-823 IC50
68 μM
Compound: Harmine
Cytotoxicity against human BGC823 cells by MTT assay
Cytotoxicity against human BGC823 cells by MTT assay
[PMID: 18462839]
Bel-7402 IC50
54 μM
Compound: 1
Cytotoxicity against human Bel7402 cells by MTT assay
Cytotoxicity against human Bel7402 cells by MTT assay
[PMID: 23291116]
Bel-7402 IC50
54 μM
Compound: Harmine
Cytotoxicity against human Bel7402 cells by MTT assay
Cytotoxicity against human Bel7402 cells by MTT assay
[PMID: 18462839]
CAKI-1 ED50
1.9 μg/mL
Compound: 3
In vitro cytotoxic activity was determined against renal cancer (CAKI-1) cell line
In vitro cytotoxic activity was determined against renal cancer (CAKI-1) cell line
[PMID: 10612592]
COLO 205 IC50
26 μM
Compound: Harmine
Antiproliferative activity against human COLO205 cells after 24 hrs by MTT assay
Antiproliferative activity against human COLO205 cells after 24 hrs by MTT assay
[PMID: 22365759]
COLO 205 IC50
46 μM
Compound: Harmine
Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay
Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay
[PMID: 22202437]
COLO 205 IC50
8 μM
Compound: Harmine
Antiproliferative activity against human COLO205 cells by MTT assay
Antiproliferative activity against human COLO205 cells by MTT assay
[PMID: 22749421]
COLO 205 IC50
8 μM
Compound: Harmine
Cytotoxicity against human COLO205 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against human COLO205 cells assessed as decrease in cell viability after 24 hrs by MTT assay
[PMID: 28216402]
DU-145 IC50
12.02 μM
Compound: Har
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay
[PMID: 29129513]
DU-145 IC50
9.63 μM
Compound: Harmine
Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay
[PMID: 31227365]
FM3A EC50
1.8 x 10-5 M
Compound: 1i, harmine
In vitro cytotoxic activity tested in mouse mammary tumor FM3A cells
In vitro cytotoxic activity tested in mouse mammary tumor FM3A cells
[PMID: 15026051]
H9 EC50
0.52 μM
Compound: 9
Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication
Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication
[PMID: 11473435]
H9 IC50
26.4 μM
Compound: 9
Cytotoxicity against human H9 cells
Cytotoxicity against human H9 cells
[PMID: 11473435]
HCT-116 IC50
43.8 μM
Compound: Harmine
Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay
[PMID: 30851694]
HCT-116 IC50
43.8 μM
Compound: Harmine
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay
[PMID: 35272009]
HCT-116 IC50
46.7 μM
Compound: Harmine
Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay
[PMID: 26555243]
HCT-116 IC50
46.7 μM
Compound: Harmine
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
[PMID: 29288941]
HCT-116 IC50
46.7 μM
Compound: Harmine
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
[PMID: 30108831]
HCT-116 IC50
6.94 μM
Compound: HM
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
[PMID: 35341920]
HCT-116 IC50
7.64 μM
Compound: HAR
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 38677112]
HCT-116 IC50
> 20 μM
Compound: Harmine
Antiproliferative activity against human HCT-116 cells
Antiproliferative activity against human HCT-116 cells
[PMID: 37875056]
HEK-293T IC50
20.98 μM
Compound: HAR
Antiproliferative activity against human HEK293T cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HEK293T cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 38677112]
HEK293 IC50
0.4 μM
Compound: Hrm
Inhibition of tetracycline-inducible EGFP-DYRK1A (unknown origin) expressed in HEK293 cells coexpressing full length human EGFP-tau protein assessed as reduction in tau-Thr212 phosphorylation incubated overnight by immunofluorescence assay
Inhibition of tetracycline-inducible EGFP-DYRK1A (unknown origin) expressed in HEK293 cells coexpressing full length human EGFP-tau protein assessed as reduction in tau-Thr212 phosphorylation incubated overnight by immunofluorescence assay
[PMID: 26896709]
HEL ED50
1.9 μg/mL
Compound: 3
In vitro cytotoxic activity was determined against embryonic lung fibroblast (HEL) cell line
In vitro cytotoxic activity was determined against embryonic lung fibroblast (HEL) cell line
[PMID: 10612592]
HGC-27 IC50
3.52 μM
Compound: Harmine
Antiproliferative activity against human HGC27 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HGC27 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31546197]
HL-60 IC50
62.45 μM
Compound: 6; Harmine
Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay
Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay
10.1039/C5MD00581G
HL-60 IC50
7.55 μM
Compound: 11
Antiproliferative activity against human HL60 cells by tryphan blue assay
Antiproliferative activity against human HL60 cells by tryphan blue assay
[PMID: 28128938]
HT-22 IC50
56.5 μM
Compound: 14
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
[PMID: 36876904]
HT-29 IC50
12.15 μM
Compound: Cpd I
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
[PMID: 38154256]
HT-29 IC50
3.52 μM
Compound: Harmine
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31546197]
HT-29 IC50
41.8 μM
Compound: Harmine
Antiproliferative activity against human HT-29 cells by MTT assay
Antiproliferative activity against human HT-29 cells by MTT assay
[PMID: 32787089]
HT-29 IC50
> 20 μM
Compound: Harmine
Antiproliferative activity against human HT-29 cells
Antiproliferative activity against human HT-29 cells
[PMID: 37875056]
HeLa IC50
16.21 μM
Compound: Har
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
[PMID: 29129513]
HeLa IC50
60 μM
Compound: 1
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
[PMID: 23291116]
HeLa IC50
60 μM
Compound: Harmine
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
[PMID: 18462839]
HeLa IC50
8 μM
Compound: Harmine
Cytotoxicity against human HeLa cells after 5 days by MTT assay
Cytotoxicity against human HeLa cells after 5 days by MTT assay
[PMID: 30193214]
HeLa IC50
85.28 μM
Compound: 6; Harmine
Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
10.1039/C5MD00581G
HeLa IC50
9.66 μM
Compound: Harmine
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay
[PMID: 31227365]
HeLa IC50
> 10 μM
Compound: Harmine
Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis
Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis
[PMID: 26555243]
HeLa IC50
> 10 μM
Compound: Harmine
Inhibition of HDAC in human HeLa nuclear extract
Inhibition of HDAC in human HeLa nuclear extract
[PMID: 30245394]
HepG2 IC50
14.93 μM
Compound: HAR
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 38677112]
HepG2 IC50
16.8 μM
Compound: HM
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
[PMID: 35341920]
HepG2 IC50
19.23 μM
Compound: Cpd I
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
[PMID: 38154256]
HepG2 IC50
46 μM
Compound: 1
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
[PMID: 23291116]
HepG2 IC50
46 μM
Compound: Harmine
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
[PMID: 18462839]
HepG2 IC50
49.96 μM
Compound: Harmine
Antiproliferative activity against human HepG2 cells by MTT assay
Antiproliferative activity against human HepG2 cells by MTT assay
[PMID: 32787089]
HepG2 IC50
51.2 μM
Compound: Harmine
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
[PMID: 29288941]
HepG2 IC50
51.2 μM
Compound: Harmine
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay
[PMID: 30108831]
HepG2 IC50
53.6 μM
Compound: Harmine
Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay
[PMID: 30851694]
HepG2 IC50
53.6 μM
Compound: Harmine
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay
[PMID: 31120744]
HepG2 IC50
> 20 μM
Compound: Harmine
Antiproliferative activity against human HepG2 cells
Antiproliferative activity against human HepG2 cells
[PMID: 37875056]
HepG2 IC50
> 250 μM
Compound: HAR
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay
[PMID: 34274829]
HepG2 IC50
> 250 μM
Compound: HAR
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay
[PMID: 35551033]
HepG2 IC50
> 250 μM
Compound: HAR
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 37696205]
HepG2 IC50
> 250 μM
Compound: Harmine
Cytotoxicity against human HepG2 cells measured after 24 hrs by neutral red assay
Cytotoxicity against human HepG2 cells measured after 24 hrs by neutral red assay
[PMID: 31812035]
Hs 683 IC50
37 μM
Compound: 1
Growth inhibition of human Hs 683 cells after 3 days by MTT assay
Growth inhibition of human Hs 683 cells after 3 days by MTT assay
[PMID: 22770529]
Hs 683 IC50
37 μM
Compound: 1, Harmine
Cytostatic activity against human Hs683 cells after 72 hrs by videomicroscopy
Cytostatic activity against human Hs683 cells after 72 hrs by videomicroscopy
[PMID: 25747498]
IMR-32 IC50
38 μM
Compound: Harmine
Antiproliferative activity against human IMR32 cells after 24 hrs by MTT assay
Antiproliferative activity against human IMR32 cells after 24 hrs by MTT assay
[PMID: 22365759]
IMR-32 IC50
68 μM
Compound: Harmine
Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay
Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay
[PMID: 22202437]
K562 IC50
14 μM
Compound: Harmine
Antiproliferative activity against human K562 cells by MTT assay
Antiproliferative activity against human K562 cells by MTT assay
[PMID: 22749421]
K562 IC50
14 μM
Compound: Harmine
Cytotoxicity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay
[PMID: 28216402]
K562 IC50
32 μM
Compound: Harmine
Antiproliferative activity against human K562 cells after 24 hrs by MTT assay
Antiproliferative activity against human K562 cells after 24 hrs by MTT assay
[PMID: 22365759]
K562 IC50
45 μM
Compound: Harmine
Cytotoxicity against human K562 cells after 24 hrs by MTT assay
Cytotoxicity against human K562 cells after 24 hrs by MTT assay
[PMID: 22202437]
K562 IC50
45 μM
Compound: Harmine
Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay
Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay
[PMID: 22516283]
KB ED50
2.2 μg/mL
Compound: 3
In vitro cytotoxic activity was determined against epidermoid carcinoma of the nasopharynx (KB) cell line
In vitro cytotoxic activity was determined against epidermoid carcinoma of the nasopharynx (KB) cell line
[PMID: 10612592]
KB ED50
2.5 μg/mL
Compound: 3
In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-VIN (expressing P-glycoprotein)
In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-VIN (expressing P-glycoprotein)
[PMID: 10612592]
KB ED50
3.7 μg/mL
Compound: 3
In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-7d (pleotrophic resistance including MRP multidrug resistant protein)
In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-7d (pleotrophic resistance including MRP multidrug resistant protein)
[PMID: 10612592]
KB ED50
4.3 μg/mL
Compound: 3
In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-CPT (pleotrophic mechanism including level of topoisomerase I)
In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-CPT (pleotrophic mechanism including level of topoisomerase I)
[PMID: 10612592]
KB IC50
57.8 μM
Compound: 7
Cytotoxicity against human epidermoid carcinoma of the nasopharynx KB cells assessed as reduction in optical density by MTT assay
Cytotoxicity against human epidermoid carcinoma of the nasopharynx KB cells assessed as reduction in optical density by MTT assay
[PMID: 23279863]
L02 IC50
25.09 μM
Compound: HM
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
[PMID: 35341920]
L02 IC50
9.49 μM
Compound: Cpd I
Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
[PMID: 38154256]
LoVo IC50
53.2 μM
Compound: Harmine
Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay
[PMID: 26555243]
LoVo IC50
53.2 μM
Compound: Harmine
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay
[PMID: 30108831]
MCF7 ED50
10.5 μg/mL
Compound: 3
In vitro cytotoxic activity against MCF-7 (human breast cancer) cell line.
In vitro cytotoxic activity against MCF-7 (human breast cancer) cell line.
[PMID: 10612592]
MCF7 IC50
10.78 μM
Compound: Har
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 29129513]
MCF7 IC50
13.37 μM
Compound: Cpd I
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
[PMID: 38154256]
MCF7 IC50
13.5 μM
Compound: HAR
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 38677112]
MCF7 IC50
15.27 μM
Compound: HM
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
[PMID: 35341920]
MCF7 IC50
16.94 μM
Compound: Harmine
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
[PMID: 33744443]
MCF7 IC50
3.52 μM
Compound: Harmine
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 31546197]
MCF7 IC50
68.33 μM
Compound: Harmine
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
[PMID: 27397495]
MCF7 IC50
70.7 μM
Compound: 6; Harmine
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
10.1039/C5MD00581G
MCF7 IC50
72 μM
Compound: Harmine
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
[PMID: 18462839]
MDA-MB-231 IC50
13.21 μM
Compound: Cpd I
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
[PMID: 38154256]
MDA-MB-231 IC50
21.91 μM
Compound: Harmine
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
[PMID: 33744443]
MDA-MB-231 IC50
32 μM
Compound: Harmine
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
[PMID: 22749421]
MDA-MB-231 IC50
32 μM
Compound: Harmine
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay
[PMID: 28216402]
MDA-MB-231 IC50
54 μM
Compound: Harmine
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay
[PMID: 22202437]
MDA-MB-231 IC50
54 μM
Compound: Harmine
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay
[PMID: 22516283]
MDA-MB-435 IC50
17.1 μM
Compound: Harmine
Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay
Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay
[PMID: 33813152]
MDA-MB-435 IC50
> 100 μM
Compound: Harmine
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 1 day by MTT assay
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 1 day by MTT assay
[PMID: 33813152]
MDCK-II GI50
2.3 μM
Compound: Harmine
Cytotoxicity against wild-type MDCK2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against wild-type MDCK2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 27280693]
MDCK-II GI50
2.42 μM
Compound: Harmine
Cytotoxicity against MDCK2 cells expressing human ABCG2 assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against MDCK2 cells expressing human ABCG2 assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 27280693]
NCI-H2228 IC50
31.06 μM
Compound: Harmine
Antiproliferative activity against human EML4-ALK positive H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human EML4-ALK positive H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 34425477]
OE33 IC50
18 μM
Compound: 1
Growth inhibition of human OE33 cells after 3 days by MTT assay
Growth inhibition of human OE33 cells after 3 days by MTT assay
[PMID: 22770529]
PC-3 IC50
15.57 μM
Compound: Cpd I
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
[PMID: 38154256]
PC-3 IC50
3.52 μM
Compound: Harmine
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 31546197]
Pancreatic beta cell EC50
7.48 μM
Compound: Telepathine
Induction of cell proliferation in rat beta cells
Induction of cell proliferation in rat beta cells
[PMID: 32077280]
Platelet IC50
130 μM
Compound: Harmine
Antiplatelet activity in rabbit platelets assessed as inhibition of collagen-induced platelet aggregation
Antiplatelet activity in rabbit platelets assessed as inhibition of collagen-induced platelet aggregation
[PMID: 21983333]
Platelet IC50
> 130 μM
Compound: Harmine
Antiplatelet aggregation activity against collagen-induced platelet
Antiplatelet aggregation activity against collagen-induced platelet
[PMID: 20329729]
SGC-7901 IC50
40.82 μM
Compound: Harmine
Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
[PMID: 27397495]
SGC-7901 IC50
70.36 μM
Compound: 6; Harmine
Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay
Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay
10.1039/C5MD00581G
SK-MEL-2 ED50
18.5 μg/mL
Compound: 3
In vitro cytotoxic activity was determined against melanoma cancer (SK-MEL-2) cell line
In vitro cytotoxic activity was determined against melanoma cancer (SK-MEL-2) cell line
[PMID: 10612592]
SK-OV-3 IC50
74.6 μM
Compound: 7
Cytotoxicity against human ovary adenocarcinoma SKOV3 cells assessed as reduction in optical density by MTT assay
Cytotoxicity against human ovary adenocarcinoma SKOV3 cells assessed as reduction in optical density by MTT assay
[PMID: 23279863]
SMMC-7721 IC50
47.6 μM
Compound: Harmine
Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay
[PMID: 30851694]
SMMC-7721 IC50
47.6 μM
Compound: Harmine
Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay
[PMID: 31120744]
SMMC-7721 IC50
55.3 μM
Compound: Harmine
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
[PMID: 29288941]
SMMC-7721 IC50
55.3 μM
Compound: Harmine
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
[PMID: 30108831]
SMMC-7721 IC50
59.44 μM
Compound: Harmine
Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay
[PMID: 27397495]
SW-620 IC50
42.8 μM
Compound: Harmine
Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay
Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay
[PMID: 26555243]
SW-620 IC50
7.32 μM
Compound: HAR
Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
[PMID: 38677112]
T98G IC50
24 μM
Compound: 1
Growth inhibition of human T98G cells after 3 days by MTT assay
Growth inhibition of human T98G cells after 3 days by MTT assay
[PMID: 22770529]
U-373MG ATCC IC50
32 μM
Compound: 1
Growth inhibition of human U373 cells after 3 days by MTT assay
Growth inhibition of human U373 cells after 3 days by MTT assay
[PMID: 22770529]
U-87MG ATCC ED50
14.5 μg/mL
Compound: 3
In vitro cytotoxic activity against U-87-MG (glioblastoma) cell line.
In vitro cytotoxic activity against U-87-MG (glioblastoma) cell line.
[PMID: 10612592]
U-87MG ATCC IC50
7.2 μM
Compound: Hrm
Growth inhibition of human U87MG cells after 4 days by MTT assay
Growth inhibition of human U87MG cells after 4 days by MTT assay
[PMID: 26896709]
In Vitro

Harmine (GMP) inhibits tau phosphorylation by DYRK1A by selected DANDYs, with an IC50 of 190 nM[2]. Harmine (GMP) negatively regulates homologous recombination (HR) by interfering Rad51 recruitment, resulting in severe cytotoxicity in hepatoma cells. Furthermore, NHEJ inhibitor Nu7441 markedly sensitizes Hep3B cells to the anti-proliferative effects of Harmine[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

It is shown that brain water content is significantly increased in the TBI group. Treatment with Harmine (GMP) significantly reduces the tissue water content at 1, 3 and 5 days, compared with the TBI group. Harmine (GMP) treatment significantly reduces the escape latency at 3 and 5 days, compared with the TBI group. Post-TBI administration of Harmine (GMP) significantly improves the motor function recovery of the rats at 1, 3 and 5 days following TBI, compared with the TBI group without Harmine (GMP) treatment. The neuronal survival rate in the Harmine (GMP)-treated group is significantly increased, compared with the TBI group. Administration of Harmine (GMP) results in marked elevation in the expression of GLT-1, compared with the TBI group. The administration of Harmine (GMP) significantly reduces the expression of caspase 3, compared with the TBI group[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

212.25

Formula

C13H12N2O

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CC1=NC=CC2=C1NC3=C2C=CC(OC)=C3

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Harmine
Cat. No.:
HY-N0737AG
Quantity:
MCE Japan Authorized Agent: